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Abstract
Background: Hypovitaminosis D is well known in different populations, but may be under diagnosed in certain
populations. We aim to determine the first diagnosis considered, the duration and resolution of symptoms, and
the predictors of response to treatment in female asylum seekers suffering from hypovitaminosis D.
Methods: Design: A pre- and post-intervention observational study.
Setting: A network comprising an academic primary care centre and nurse practitioners.
Participants: Consecutive records of 33 female asylum seekers with complaints compatible with osteomalacia and
with hypovitaminosis D (serum 25-(OH) vitamin D <21 nmol/l).
Treatment intervention: The patients received either two doses of 300,000 IU intramuscular cholecalciferol as
well as 800 IU of cholecalciferol with 1000 mg of calcium orally, or the oral treatment only.
Main outcome measures: We recorded the first diagnosis made by the physicians before the correct diagnosis of
hypovitaminosis D, the duration of symptoms before diagnosis, the responders and non-responders to treatment,
the duration of symptoms after treatment, and the number of medical visits and analgesic drugs prescribed 6
months before and 6 months after diagnosis.
Tests: Two-sample t-tests, chi-squared tests, and logistic regression analyses were performed. Analyses were
performed using SPSS 10.0.
Results: Prior to the discovery of hypovitaminosis D, diagnoses related to somatisation were evoked in 30
patients (90.9%). The mean duration of symptoms before diagnosis was 2.53 years (SD 3.20). Twenty-two patients
(66.7%) responded completely to treatment; the remaining patients were considered to be non-responders. After
treatment was initiated, the responders' symptoms disappeared completely after 2.84 months. The mean number
of emergency medical visits fell from 0.88 (SD 1.08) six months before diagnosis to 0.39 (SD 0.83) after (P =
0.027). The mean number of analgesic drugs that were prescribed also decreased from 1.67 (SD 1.5) to 0.85 (SD
1) (P = 0.001).
Conclusion: Hypovitaminosis D in female asylum seekers may remain undiagnosed, with a prolonged duration
of chronic symptoms. The potential pitfall is a diagnosis of somatisation. Treatment leads to a rapid resolution of
symptoms, a reduction in the use of medical services, and the prescription of analgesic drugs in this vulnerable
population.
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Background
Deficiency of vitamin D, leading to osteoporosis and
osteomalacia, is well known in elderly people in Western
countries. A European survey in community dwellers over
70 years showed hypovitaminosis D (25- [OH] vitamin D
<30 nmol/l) in 36% of men and 47% of women [1].
Hypovitaminosis D and osteomalacia have also been
reported in the immigrant Indo-Asian population in the
UK since the 1960's [2-5]. Yet this disorder remains widely
underconsidered according to more recent studies, with
one reporting a mean period of 59.2 months of com-
plaints before the diagnosis was established [6], and
another reporting a prevalence of 78% of hypovitamino-
sis D (versus 58% in controls) in an Indo-Asian popula-
tion attending a rheumatology clinic in the UK [7].
A recent study in the United States showed that of 150
consecutive patients (immigrant and non-immigrant) of a
community clinic with persistent, non-specific muscu-
loskeletal pain, 100% had vitamin D insufficiency (<50
nmol/l) and 28% had severe deficiency (<20 nmol/l) [8].
We have also previously reported eleven cases of sympto-
matic hypovitaminosis D in female asylum seekers [9].
The condition has also been assessed in consecutively
admitted medical inpatients: 57% were considered vita-
min D deficient (<37.5 nmol/l), of whom 22% were
severely deficient (<20 nmol/l) [10].
Finally, in recent years, several studies have examined the
prevalence of hypovitaminosis D in healthy subjects [11-
13]. In the late winter months, it appears that 36% of
young healthy adults in Boston suffer from the condition
(25-(OH) vitamin D <50 nmol/l) [13] as well as 34% of
healthy adults in Brussels (25-(OH) vitamin D <40 nmol/
l) [12].
Thus, the disease is more prevalent than we generally sus-
pect, not only in at-risk individuals in our multicultural
societies, but probably also in a population that appears
less vulnerable.
Concerning treatment, the benefit of the prophylactic use
of vitamin D and calcium has been established in Asian
immigrants in the UK [14], as well as in elderly subjects in
regard to its effect on fractures and falls [15,16]. Hardly
any studies have measured the impact or clinical response
to treatment over time in a younger immigrant popula-
tion. We are aware of one study, on osteomalacic myopa-
thy in veiled Arabic women in Denmark with a mean age
of 32.2 years, that demonstrated a normalisation of mus-
cle strength (except in maximal voluntary contraction) at
6 months after initiation of treatment [17].
The purpose of the study was to assess the impact of diag-
nosis and treatment in female asylum seekers with hypo-
vitaminosis D. We first noted the diagnosis made by the
primary care physicians, as well as the delay in the estab-
lishment of the diagnosis of hypovitaminosis D. We then
assessed the response to treatment by these parameters:
improvement of clinical symptoms (bone pain, muscle
weakness, and fatigue), variation in the number of analge-
sic drugs prescribed, and number of medical visits before
and after treatment.
Concerning the response to treatment, no predictors have
yet been defined. We therefore tried to extract from our
study variables such as age, length of stay in Switzerland,
number of chronic illnesses, and existence of psychiatric
comorbidity as possible predictors of a positive response
to treatment.
Methods
Patients
The study investigated female asylum seekers attending an
academic primary care centre serving a population of
100,000 between March 2000 and April 2002. All of the
patients belong to a health network with a nurse practi-
tioner gate-keeping system and primary care physicians.
The patients must always consult within this setting and
cannot change their primary care physician without
informing the nurse practitioner. After a certain number
of cases of hypovitaminosis D were diagnosed in 2000,
the centre's primary care physicians were informed by two
circular letters, in March and April 2001, of the suspected
high prevalence of this disease in female asylum seekers,
particularly those with a minimal exposure to sunlight
and presenting with a history of bone pain, proximal mus-
cular weakness, a change in gait and/or fatigue. In sus-
pected cases seen within the outpatient department
(emergencies and follow-ups), we checked serum levels of
25-(OH) vitamin D, while the physician determined
other biochemical parameters if judged necessary: cal-
cium, phosphate, alkaline phosphatase, and parathyroid
hormone (PTH). We included women with symptoms of
hypovitaminosis D and a confirmed deficiency in the
study. Only women were included because of their risk
factors and histories. There were no exclusion criteria. In
our setting, we did not constitute a control group. The
physicians were asked several times to report their cases,
but we did not revise all files systematically. The physi-
cians were advised to follow treatment recommendations
specified in the circular letters (300,000 IU of intramuscu-
lar cholecalciferol with an ongoing course of 800 IU of
cholecalciferol associated with 1000 mg of calcium), but
were free not to do so. Therefore, the decisions to dose 25-
(OH) vitamin D, to report the cases, and to treat, if neces-
sary, the patients, were left to the physicians who were
directly in charge of the patients. Nevertheless, we dis-BMC Family Practice 2006, 7:4 http://www.biomedcentral.com/1471-2296/7/4
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cussed the two circular letters extensively with the primary
care physicians and had informal discussions as well.
No approval from a ethics committee was required for this
study. Indeed, in Switzerland, a chart review does not
need an ethical committee acceptance. All the patients
included in the study gave their consent concerning the
treatment that is appropriate for hypovitaminosis D. Fur-
thermore, the physicians were free to follow treatment rec-
ommendations.
Study design and treatment
The study was a prospective observational study. Guide-
lines for treatment were suggested in the circular letters
and the majority of patients received two intramuscular
injections of 300,000 IU of cholecalciferol at monthly
intervals, as well as an ongoing course of oral calcium
(1000 mg) and cholecalciferol (800 IU = 20 µg). After 6
months follow-up, we reviewed the medical and nurse
practitioner records to determine the main outcomes.
There was no standardized questionnaire designed for the
follow-up. The information was retrieved from the files
with an extraction sheet only.
25-(OH) vitamin D was measured by a radioimmu-
noassay (RIA) with an 125I-labelled tracer (DiaSorin Inc.).
Calcium and phosphate levels were measured by spectro-
photometry (Roche). The reference ranges are 21–131
nmol/l for 25-(OH) vitamin D, 2.15–2.55 mmol/l for cal-
cium and 0.8 – 1.6 mmol/l for phosphate. (For 25-(OH)
vitamin D, 1 µg/l = 2.5 nmol/l). The reference range for
25-(OH) vitamin D is derived from a group of 20 male
and 24 female healthy, predominately Caucasian volun-
teers from the midwestern USA, aged between 23 and 67
years, during the month of October (DiaSorin Inc.). It is
well known, however, that this reference range describes a
severe hypovitaminosis D, and that levels below 50 nmol/
l are considered insufficient (see Discussion section).
Outcomes
We determined a number of parameters, including region
of origin, length of stay in Switzerland, first diagnosis,
Biochemical results (25-(OH) vitamin D and calcium) of patients at the time of diagnosis Figure 1
Biochemical results (25-(OH) vitamin D and calcium) of patients at the time of diagnosis.
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number of months prior to diagnosis, number of chronic
illnesses, psychiatric comorbidity, number of visits and
emergency visits six months before and six months after
diagnosis, number of analgesic drugs prescribed 6 months
before and 6 months after diagnosis, resolution of symp-
toms after treatment (we defined two categories: complete
resolution of symptoms as responders and partial or no
resolution as non-responders) and duration of resolution
(partial or complete).
Statistics
Two-sample t-tests, chi-squared tests, and logistic regres-
sion analyses were performed. Analyses were performed
using SPSS 10.0.
Results
The study population comprised 18 (54.5%) Somali
women, 12 (36.4%) Balkan women, and 3 (9.1%)
women of other origin. The mean age was 38.8 years (SD
16.9). Twenty-three (69.7%) of the women wore a veil
(partial or complete, including gloves), and no corre-
sponding details were available for 2 patients (6.1%). The
population had been residing in Switzerland for a mean
period of 5.27 years (SD 3). The patients were suffering
from a mean of 2.76 chronic illnesses, such as, iron defi-
ciency with or without anaemia, obesity, gastritis, tension
headache, and hypertension (SD 1.97), and 10 patients
(30.3%) were considered to have one or more psychiatric
diagnoses other than somatisation.
The first diagnoses, before hypovitaminosis D was consid-
ered, were chronic back pain, generally associated with
pelvic or rib pain, in 17 patients (51.5%); somatisation
disorder in 7 patients (21.2%); and multiple unexplained
somatic symptoms in 6 patients (18.2%). Regrouping
these different diagnoses, we obtain a total of 90.1% of
patients with an initial diagnosis related to somatisation.
In 3 patients (9.1%), the diagnosis of hypovitaminosis D
was mentioned initially. The physicians treating these 3
new patients had been formerly informed of the possible
high prevalence of the disease prior to the consultation
and had suspected it on presentation.
The mean duration of symptoms before diagnosis was
2.53 years (SD 3.20). The duration of symptoms after see-
ing a physician in our centre was 1.87 years (SD 2.20).
Nevertheless, in retrospect, the majority of complaints
were quite typical of hypovitaminosis D from the outset.
Mean number of emergency medical visits 6 months before and 6 months after diagnosis Figure 2
Mean number of emergency medical visits 6 months before and 6 months after diagnosis.
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On diagnosis, the mean serum 25-(OH) vitamin D level
was 11.32 nmol/l (SD 4.55). Most of these measurements
(87.9%, 29 patients) were made from November to May,
at a time when sunshine levels are low (latitude 46.3°).
For 28 patients (84.8%), the mean blood calcium level on
diagnosis was 2.17 mmol/l (SD 0.09), and 42.9% of these
patients had hypocalcaemia (<2.15), with a minimum of
1.92 mmol/l.
Phosphate concentrations were measured in 25 patients
(75.7%), and the mean level was 0.98 mmol/l (STD 0.31).
Of these patients, 32% were hypophosphataemic (<0.8)
and none were hyperphosphataemic.
Treatment consisted only of calcium and cholecalciferol
p.o. in 10 patients (30.3%). The remaining 23 received, in
addition, the two injections of cholecalciferol.
With regard to symptom resolution, 22 patients (66.7%)
experienced complete resolution and 11 (33.3%) pre-
sented either partial (n = 6) or no resolution (n = 5). The
beginning of symptom resolution in responders was
already noted at 1.47 months (SD 0.59), and resolution
was complete at 2.84 months (SD 1.76). One patient
required seven months of treatment to be free from symp-
toms.
Three patients did not consult the primary care physician
or the nurse practitioner in relation to the symptoms of
hypovitaminosis D after initiation of treatment. They
were considered to be responders to treatment, since the
medical facilities were totally accessible to them and, on
the two occasions on which they did consult the nurse,
they did not complain of their initial symptoms.
During the whole period preceding diagnosis, the patients
received a mean of 3.27 analgesic drugs (SD 2.28), com-
pared to a mean of 1.67 (SD 1.51) during the 6 months
before diagnosis. In the 6 months after diagnosis and ini-
tiation of treatment, the number of analgesic drugs fell to
0.85 (SD 1), (P = 0.001). Certain patients suffered from
chronic medical conditions (tension headache, osteoar-
thritis, irritable bowel syndrome, migraine) requiring
analgesic medication that did not vary significantly over
the 12-month period for which we analysed the data.
Mean number of analgesic drugs 6 months before and 6 months after diagnosis Figure 3
Mean number of analgesic drugs 6 months before and 6 months after diagnosis.
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We analysed the follow-up visits and the emergency visits.
Our centre was open 24 hours a day, 7 days a week. After
diagnosis, 27 patients (81.8%) received a medical follow-
up in our centre, 3 patients (9.1%) changed physician
after at least one medical visit, and the remaining 3
(9.1%) were followed up by the nurse practitioners. There
was no difference between the follow-up visits before and
after diagnosis. However, the emergency visits fell from
0.88 (SD 1.08) six months before diagnosis to 0.39 (SD
0.83) six months after (P = 0.027).
In a univariate analysis we analysed age, length of stay in
Switzerland, number of chronic illnesses, psychiatric
comorbidity, presence of a veil, level of 25-(OH) vitamin
D, and duration of symptoms before diagnosis, in relation
to the resolution of symptoms. None of these variables
was significant. According to our logistic regression analy-
sis, neither age, nor the number of chronic illnesses, nor
the existence of psychiatric comorbidity were predictors of
the response to treatment.
Discussion
Our results suggest that hypovitaminosis D is still going
undiagnosed in immigrant women. Indeed, the first diag-
nosis evoked, in an often psychologically difficult context,
is one suggestive either of somatoform disorder as
described in the International Classification of Diseases,
10th revision [18] or "somatisation" as defined in the
study of Simon et al [19]. In this study, we refer particu-
larly to the definition concerning patients with psycholog-
ical disorders who report multiple unexplained somatic
symptoms. Nevertheless, pain due to hypovitaminosis D
is quite well defined. It is felt in the bones, not in the
joints. In general, it is symmetrical, beginning in the lower
back and then spreading to the pelvis, upper legs, and ribs.
The patients may also present with proximal muscle weak-
ness.
In our study, the complaints lasted for a considerable
length of time, with important psychosocial repercussions
in an already vulnerable population. This reflects the poor
knowledge of hypovitaminosis D prevalent in a group of
Swiss primary care physicians, and confirms the study by
Nellen [6]. The impact of information is important, lead-
ing in our study to the diagnosis of 33 new cases in a year
and a half. We wish to emphasize the importance of the
diagnosis in a female Balkan population, a group in which
osteomalacia has not yet been formally described. Only
one-third of these patients wore a veil, so there is no direct
correlation between these two parameters. It is neverthe-
less possible that global sun exposure (due to house-
bound status) is limited, and that dietary factors have an
influence in this population.
After treatment, subjective improvement was already
present after a mean of 1.47 months, and resolution was
complete after a mean of 2.84 months, with complete res-
olution at a maximum of 7 months in all patients who
responded to treatment. The resolution of symptoms is
known to occur approximately between 3 and 6 months:
3 months for symptoms due to the osteopathy [6] and 6
months for the myopathy [17].
Our results also show a reduction in the use of medical
services and the prescription of analgesic drugs. These
results should be considered preliminary, because no con-
trol group was constituted. Nevertheless, these two facts
could be of primary importance. The reduction in emer-
gency visits, not necessarily linked to hypovitaminosis D,
probably reflects a general improvement in well-being,
compared to periods when the patients were suffering
from chronic pain. This has not been evaluated, but there
may have been an improvement in psychological factors
that elevated the threshold for an emergency medical visit.
Secondly, the reduction in the prescription of analgesic
drugs is probably paralleled by a reduction in use, as all
NSAIDs in Switzerland are obtained on prescription and
the population studied possesses limited financial
resources, which limit its access to over-the-counter drugs.
The probable reduction in use also reduces the potential
harmful side effects, particularly those associated with
NSAIDs. The economic impact of these two results has not
been established, but is another interesting consideration.
In the studied population, we found very low levels of 25-
(OH) vitamin D, which is regarded as the best laboratory
indicator of functional vitamin D status [20]. Over the
past few years, this status has been regaining considerable
attention. Vitamin D receptors are found not only in bone
and muscle but also in the breast, colon, prostate,
immune system, brain, and probably other tissues of the
body. Vitamin D deficiency affects bone metabolism, and
results in osteoporosis and osteomalacia (or rickets, in
children), and evidence is now emerging that hypovitami-
nosis D has other important adverse effects on health,
such as increasing the risks of autoimmune diseases, can-
cers, and other chronic affections [21-23]. A long-term
study of 180,000 women showed that women taking 400
IU of vitamin D daily had 40% less risk of developing MS
than those who did not [24]. The risks of prostate and
colon cancer are lower if 25-(OH) vitamin D levels are
above 50 nmol/l [25-27]. In this context, the optimal lev-
els of vitamin D for health benefits have been subject to a
number of discussions and studies. It is now widely
accepted that 25-(OH) vitamin D levels below 20 nmol/l
are indicative of severe deficiency [28]. Levels of at least 50
nmol/l [29], and according to some authors, 78 nmol/l
[30], are necessary to prevent secondary hyperparathy-
roidism. Recent evidence showed that calcium is malab-BMC Family Practice 2006, 7:4 http://www.biomedcentral.com/1471-2296/7/4
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sorbed and fracture risk increases at serum levels below
~80 nmol/l [31]. A 25-(OH) vitamin D level between 80
and 125 nmol/l seems optimal for general health
[21,22,31]. Risk factors (reduced exposure to sunlight and
strict vegetarian diet) [10,32,33] must be minimized to
achieve these concentrations. Nevertheless, these risk fac-
tors are difficult to modify; even in Australia, the paradox
of hypovitaminosis D in a sunny country is emerging as a
public health problem [34]. The most cost-effective way to
reach optimal levels of 25-(OH) vitamin D is increasing
UVB exposure, by exposing the hands, arms, and face, if
culturally acceptable and with caution in low latitudes,
without sunscreen for 5–15 min between 1000 and 1500
h in the spring, summer, and fall for individuals with type
II and III skin. Diet does not provide high doses of vitamin
D, since very few foods contain it (oily fish being one) and
fortified food has not met public health expectations.
Routine supplementation could be the only effective way
of preventing hypovitaminosis D in the population
described in our study, since it is not likely that sun expo-
sure habits and diet will change to any meaningful extent.
For example, a large educational campaign within the
Asian community of Rochdale, UK, between 1970 and
1980 only resulted in an improvement of biochemical
markers of vitamin D deficiency among the children [35].
The benefits of treatment seem clear in our symptomatic
vitamin D deficient population, even though we only
assessed them by direct questioning and by indirect
parameters, as it has been done in other fields [36]. We
did not have the set-up to evaluate treatment by costly or
invasive methods (dynamometer testing or bone biopsy).
The use of vitamin D in Asian immigrants in the UK has
been assessed only with biochemical markers [14], dem-
onstrating a response by serum levels of 25-(OH) vitamin
D after oral supplementation and no change in the levels
of calcium, phosphate, and alkaline phosphatase. But, as
we have revealed, hypovitaminosis D concerns a much
wider population, including immigrants and non-immi-
grants, and young and old. One very interesting study
showed the effectiveness of an annual megadose of intra-
muscular cholecalciferol (600,000 IU) in patients with
vitamin D deficiency. This therapy appears to be safe, even
if certain concerns, such as hypercalciuria, need to be
examined. This treatment could potentially be applied on
a large scale [37]. Two recent meta-analyses concerning
elderly people have shown that intakes of >700 IU are
necessary to decrease by approximately 25% (hip, NNT
45/non-vertebral, NNT 27) and 22% (NNT 15) the risk of
fractures and falls, respectively [15,16]. The present Rec-
ommended Daily Amounts (RDA) in the United States are
200 IU (5 µg) daily for young adults, 400 IU (10 µg) for
those aged 51–70, and 600 IU (15 µg) daily for those over
71 years of age [38]. Generally, experts recommend a daily
intake of 800–1000 IU per day for concrete benefits in
health [39,40]. The mode and frequency of administra-
tion remain to be studied in different populations.
In this small group of patients, the parameters studied
(age, length of stay in Switzerland, chronic illness, psychi-
atric co morbidity, veil, and level of 25-(OH) vitamin D
were not predictive of response or non-response.
Our study clearly suffers from a number of limitations.
First, the study lacks a control group. Second, we do not
know the number of patients that were not included in
the study because of failure of the physicians to properly
record the data. Third, we do not possess the complete
biochemical data for all the patients (alkaline phos-
phatase, PTH, and albumin). Finally, the records can occa-
sionally be imprecise in the descriptions of symptoms and
diagnoses.
In conclusion, in the context of resurgent scientific inter-
est in vitamin D, hypovitaminosis D must be considered
in a symptomatic, female, asylum-seeking population, to
avoid prolonging the duration of chronic symptoms and
a potential misdiagnosis of somatisation. The impact of
treatment is beneficial, with a rapid resolution of symp-
toms and reductions in both the use of medical services
and the prescription of analgesic drugs. Physicians should
therefore be aware of the importance of this disease and
the impact of rapid diagnosis and treatment. Future
research will have to consider the need for routine supple-
mentation in this and other populations.
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